US$30.9 million strategic equity deal strengthens oncology platform

MB310 study investigates safety and efficacy of precision microbiome therapy

Four-year treatment slows cognitive decline with consistent safety profile

Spikevax authorised to target LP.8.1 variant ahead of 2025-2026 season

Alfasigma to seek regulatory approval following OLINGUITO study success

Imfinzi and Imjudo combination recommended as first-line treatment

CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy

CHMP recommends authorization for LP.8.1-targeting vaccine ahead of 2025-2026 season

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in […]

Collaboration aims to advance next-generation therapeutics and vaccines